Following a Phase II release of data for its oral histone deacetylase inhibitor pracinostat in the tough-to-treat acute myeloid leukemia indication, MEI Pharma Inc. CEO Dan Gold said he is optimistic heading into Phase III with Swiss partner Helsinn Group, during an interview with Scrip's Emily Hayes at the Biotech Showcase.
MEI Pharma Rides Wave Of Interest in AML
MEI Pharma CEO Dan Gold explains Phase III plans for the oral HDAC inhibitor pracinostat in acute myeloid leukemia and why there is still room in the market for a new PI3 kinase inhibitor like MEI-401 in B-cell malignancies in an interview at the Biotech Showcase.
More from Start-Ups & SMEs
More from Business
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.